Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct-Dec;7(4):254-257.
doi: 10.4103/sajc.sajc_18_17.

Safety and efficacy of weekly versus three-weekly paclitaxel plus platinum neoadjuvant chemotherapy in patients with locally advanced squamous cell head and neck carcinoma: A pilot study

Akash Mathur  1 , Naincy Rastogi  2 , Dinesh Gurjar  1 , Ramkrishna Sai  1 , Arvind Lakesar  1 , Hemant Malhotra  1
Affiliations

Safety and efficacy of weekly versus three-weekly paclitaxel plus platinum neoadjuvant chemotherapy in patients with locally advanced squamous cell head and neck carcinoma: A pilot study

Akash Mathur et al. South Asian J Cancer. 2018 Oct-Dec.

Abstract

Background: Squamous cell carcinoma of head and neck (SCCHN) is one of the most common cancers seen in India and also the world. Majority of patients present in locally advanced (LA) disease where neoadjuvant combination chemotherapy with a taxane plus platinum with/without 5-Fluorouracil is the standard of care treatment. There are no/few prospective trials of weekly paclitaxel in SCCHN in spite of convincing evidence regarding safety and tolerability in other solid tumors such as breast, ovary, and lung carcinoma. In the present study, we prospectively assessed the safety and efficacy of weekly versus three-weekly paclitaxel plus platinum neoadjuvant chemotherapy in patients with LA-SCCHN.

Materials and methods: We included 50 newly diagnosed patients of LA-SCCHN in the study and randomized them into two groups to receive either low-dose weekly (80 mg/sq. m) or standard three-weekly (175 mg/sq. m) paclitaxel along with standard dose carboplatin (AUC 5) and assessed response rates and toxicities.

Results: Age and sex were evenly matched in both groups. Oral and oropharyngeal cancers were the most common sites. Hematological toxicities were significantly more in the three-weekly group. Nonhematological toxicities, especially neuropathy, were also more in this group. The overall response rate (complete response + partial response) in the three-weekly arm was 36% versus 52% in the weekly arm.

Conclusion: Data from our small study suggest that weekly paclitaxel plus platinum neoadjuvant chemotherapy may be superior to the standard every 3 weeks' administration in terms of safety as well as efficacy in patients with LA-SCCHN.

Keywords: Head and neck malignancies; neoadjuvant chemotherapy; paclitaxel; squamous cell carcinoma of the head and neck.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Distribution of the cases according to follow-up at 2, 4, and 6 months
See this image and copyright information in PMC

References

    1. Sharma RG, Kapoor R, Bang BA, Gurjar K. Spectrum of malignancies in Jaipur region (2004-2008) Indian J Cancer. 2014;51:45–53. - PubMed
    1. Vokes EE. Induction chemotherapy for head and neck cancer: Recent data. Oncologist. 2010;15(Suppl 3):3–7. - PubMed
    1. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005;23:5983–92. - PubMed
    1. Shimizu T, Yokoi T, Tamaki T, Kibata K, Inagaki N, Nomura S, et al. Comparative analysis of carboplatin and paclitaxel combination chemotherapy schedules in previously untreated patients with advanced non-small cell lung cancer. Oncol Lett. 2013;5:761–7. - PMC - PubMed
    1. Harano K, Terauchi F, Katsumata N, Takahashi F, Yasuda M, Takakura S, et al. Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016) Ann Oncol. 2014;25:251–7. - PubMed